Survival outcome of patients with nasopharyngeal carcinoma with first local failure: A study by the Hong Kong Nasopharyngeal Carcinoma Study Group

Yu, Kin Wah; Leung, Sing-fai; Tung, Stewart Y.; Zee, Benny; Chua, Daniel T.T.; Sze, W.M.; Law, Stephen C.K.; Kam, Michael Koon Ming; Leung, TW; Sham, Jonathan S. T.; Lee, Anne W.M.; Au, Joseph Siu-Kie; Hui, Edwin P.; Sze, Wing Kin; Cheng, Ashley; Yau, Tsz Kok; Ngan, Roger K.C.; Wong, F.; Au, Gordon K.H.; Chan, Anthony T.C.

doi:10.1002/hed.20161

Cited by 164 publications

(150 citation statements)

References 33 publications

(96 reference statements)

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…In a cohort of 200 patients with isolated rnpc, patients who received radiotherapy or surgery (or both) experienced better survival than did patients who received chemotherapy and supportive treatment 33 . However, because of the technical difficulties of surgery or radiotherapy and the lack of effective chemotherapeutic agents, rnpc was previously viewed mainly as an incurable disease, with patients receiving palliative treatment.…”

Section: Purpose Of Re-treatment: Curable or Palliative?mentioning

confidence: 99%

“…As summarized in Figure 1, the T stage and histologic type of the recurrent tumour, the patient's age, the interval between initial treatment and recurrence, and factors influencing treatment are important prognostic factors in rnpc. Of the foregoing factors, T stage of the recurrent tumour is the most important 5,6,18,[33][34][35] . In a prospective study by Lee et al 18 , the 5-year local control and os rates for rT3 were distinctly lower than those for rT1 (11% and 4% vs. 35% and 27% respectively).…”

Section: Purpose Of Re-treatment: Curable or Palliative?mentioning

confidence: 99%

See 1 more Smart Citation

Recurrent Nasopharyngeal Carcinoma: A Clinical Dilemma and Challenge

et al. 2013

View full text Add to dashboard Cite

Recurrent nasopharyngeal carcinoma, which represents a small proportion of head-and-neck cancers, has a unique set of patho-clinical characteristics. The management of recurrent nasopharyngeal carcinoma remains a challenging clinical problem. Traditional treatments offer limited local control and survival benefits; more seriously, they frequently induce severe late complications. Recently, novel treatment techniques and strategies—including precision radiotherapy, endoscopic surgery or transoral robotic resection, third-generation chemotherapy regimens, and targeted therapies and immunotherapy—have provided new hope for patients with recurrent nasopharyngeal carcinoma. Some of these patients can potentially be cured with modern treatments. However, a lack of adequate evidence makes it difficult for clinicians to apply these powerful techniques and strategies. Individualized management guidelines, full evaluation of quality of life in these patients, and a further understanding of the mechanisms underlying recurrence are future directions for research into recurrent nasopharyngeal carcinoma.

show abstract

Section: Purpose Of Re-treatment: Curable or Palliative?mentioning

confidence: 99%

Section: Purpose Of Re-treatment: Curable or Palliative?mentioning

confidence: 99%

Recurrent Nasopharyngeal Carcinoma: A Clinical Dilemma and Challenge

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The Hong Kong Nasopharyngeal Carcinoma Study Group [16] reported in retrospective study the rate of survival rate patients with isolated local failure was 74%, 4 patients died in consequence of radiotherapy complication. The late toxicity is a limiting factor for reirradiation.…”

Section: Discussionmentioning

confidence: 99%

Brachytherapy in Reirradiation of Locally Recurrent Nasopharyngeal Cancer: Case Report

Toulba¹,

Bakkali²,

Diabate³

et al. 2017

IJRRT

View full text Add to dashboard Cite

Purpose: Nasopharyngeal carcinoma (NPC) is a most cancer of head and neck in North Africa and South East Asia. The risk of local recurrence after treatment is higher. Reirradiation can be difficult and limited by the constraints of doses to organs at risk already irradiated. The aim of this study was to determine the role of brachytherapy in safety reirradiation of recurrent NPC. Methods and Materials:From 2002 to 2011, five patients were reirradiated for local recurrence nasopharyx cancer with or without external beam radiotherapy (EBRT). Results:The median age was 49 years, all were male, four patients had World Health Organization Class III histology, and one with nasopharyx cancer type I. Two, 1 and 2 patients had recurrent Stage I, II, III, respectively. Median time to reirradiation was 49 months. Four patients received combined-modality treatment, consisting of external beam radiotherapy (EBRT) with chemotherapy followed by intracavitary brachytherapy High Dose Rate (HDR) boost, one patient received intracavitary brachytherapy alone for dosimetric constraints for organs at risk. The total radiation dose EQD2 was between 60 and 70Gy. All patients received concomitant chemotherapy and two neoadjuvant chemotherapy. The median follow-up for all patients was 40 months; one patient developed an immobility of the soft palate and another had grade II trismus. Conclusion:Brachytherapy alone or after EBRT may play an important role in reirradiation of locally recurrent NPC with acceptable toxicity.

show abstract

“…It is still challengeable to increase local control rate for staged T3-4 patients (Yu et al, 2005), in recent years, along with the application of intensity modulated radiation therapy technique, local control rate of nasopharyngeal carcinoma is increased further without increasing late irradiation-related complications due to its best coverage advantage (Lu et al, 2008;Kim et al, 2009;Lin et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

Preliminary Results of a Phase I/II Study of Simultaneous Boost Irradiation Radiotherapy for Locally Advanced Nasopharyngeal Carcinoma

Xiang

Wang²,

Xu³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

7%) showing partial remission.The most frequently observed acute toxicities during the concurrent chemoradiotherapy were mucositis and leucopenia. Four patients (6.9%) had RTOG grade 3 mucositis, whereas four patients (6.9%) had grade 3 leucopenia. No patient had grade 4 acute toxicity. Three (5.17%) of the patients exhibited injury to the brain on routine MRI examination, with a median observation of 32 months (range, 25-42months). All of them were RTOG grade 0. The 3-year overall, regional-free and distant metastasis-free survival rates were 85%, 94% and 91%, respectively. Conclusion: Simultaneous boost irradiation radiotherapy is feasible in patients with locally advanced nasopharyngeal carcinoma. The results showed excellent local control and overall survival, with no significant increase the incidence of radiation brain injury or the extent of damage. A larger population of patients and a longer follow-up period are needed to evaluate ultimate tumor control and late toxicity.

show abstract

Survival outcome of patients with nasopharyngeal carcinoma with first local failure: A study by the Hong Kong Nasopharyngeal Carcinoma Study Group

Cited by 164 publications

References 33 publications

Recurrent Nasopharyngeal Carcinoma: A Clinical Dilemma and Challenge

Recurrent Nasopharyngeal Carcinoma: A Clinical Dilemma and Challenge

Brachytherapy in Reirradiation of Locally Recurrent Nasopharyngeal Cancer: Case Report

Preliminary Results of a Phase I/II Study of Simultaneous Boost Irradiation Radiotherapy for Locally Advanced Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About